Tandem Diabetes Valuation
| TNDM Stock | USD 33.47 0.86 2.64% |
At this time, the company appears to be undervalued. Tandem Diabetes Care has a current Real Value of $42.1 per share. The regular price of the company is $33.47. Our model measures the value of Tandem Diabetes Care from inspecting the company fundamentals such as Shares Outstanding of 65.68 M, operating margin of (0.11) %, and Return On Equity of -0.46 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Tandem Diabetes' valuation include:
Undervalued
Today
Please note that Tandem Diabetes' price fluctuation is very steady at this time. Calculation of the real value of Tandem Diabetes Care is based on 3 months time horizon. Increasing Tandem Diabetes' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Tandem stock is determined by what a typical buyer is willing to pay for full or partial control of Tandem Diabetes Care. Since Tandem Diabetes is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tandem Stock. However, Tandem Diabetes' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 33.47 | Real 42.1 | Target 51.1 | Hype 33.5 |
The intrinsic value of Tandem Diabetes' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Tandem Diabetes' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Tandem Diabetes Care helps investors to forecast how Tandem stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tandem Diabetes more accurately as focusing exclusively on Tandem Diabetes' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Tandem Diabetes' intrinsic value based on its ongoing forecasts of Tandem Diabetes' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Tandem Diabetes' closest peers.
Tandem Diabetes Cash |
|
Tandem Valuation Trend
Knowing Tandem Diabetes' actual value is paramount for traders when making sound investment determinations. Using both Tandem Diabetes' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Tandem Revenue by Product
Tandem Diabetes Total Value Analysis
Tandem Diabetes Care is at this time forecasted to have valuation of 2.2 B with market capitalization of 2.2 B, debt of 415.67 M, and cash on hands of 608.73 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Tandem Diabetes fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.2 B | 2.2 B | 415.67 M | 608.73 M |
Tandem Diabetes Investor Information
About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 494.25. Tandem Diabetes Care recorded a loss per share of 1.94. The entity last dividend was issued on the 10th of October 2017. The firm had 1:10 split on the 10th of October 2017. Based on the key indicators related to Tandem Diabetes' liquidity, profitability, solvency, and operating efficiency, Tandem Diabetes Care is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Tandem Diabetes Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Tandem Diabetes has an asset utilization ratio of 78.49 percent. This suggests that the Company is making $0.78 for each dollar of assets. An increasing asset utilization means that Tandem Diabetes Care is more efficient with each dollar of assets it utilizes for everyday operations.Tandem Diabetes Ownership Allocation
The majority of Tandem Diabetes Care outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tandem Diabetes to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tandem Diabetes Care. Please pay attention to any change in the institutional holdings of Tandem Diabetes Care as this could imply that something significant has changed or is about to change at the company. On September 11, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Tandem Diabetes Care's common stock.Tandem Diabetes Profitability Analysis
The company reported the previous year's revenue of 747.72 M. Net Loss for the year was (222.61 M) with profit before overhead, payroll, taxes, and interest of 425.41 M.About Tandem Diabetes Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Tandem Diabetes Care. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Tandem Diabetes Care based exclusively on its fundamental and basic technical indicators. By analyzing Tandem Diabetes's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Tandem Diabetes's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Tandem Diabetes. We calculate exposure to Tandem Diabetes's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Tandem Diabetes's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 422.8 M | 444 M | |
| Pretax Profit Margin | (0.27) | (0.28) | |
| Operating Profit Margin | (0.28) | (0.29) | |
| Net Loss | (0.27) | (0.28) | |
| Gross Profit Margin | 0.44 | 0.27 |
Tandem Diabetes Growth Indicators
Investing in growth stocks can be very risky. If the company such as Tandem Diabetes does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 65 M | |
| Quarterly Earnings Growth Y O Y | -0.37 | |
| Forward Price Earnings | 1111.1111 |
Tandem Diabetes Current Valuation Indicators
Tandem Diabetes' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Tandem Diabetes' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Tandem Diabetes, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Tandem Diabetes' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Tandem Diabetes' worth.When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.